Allopurinol (C09-0734-816)

InformationAllopurinol Allopurinol is a purine analog inhibitor of the enzyme xanthine oxidase , used to treat gout or kidney stones, and to decrease levels of uric acid.In vitroAllopurinol reverses the increased xanthine oxidase activity in ischemia-reperfusion injury of neonatal rat hearts. Allopurinol (10 mM) treatment suppresses xanthine oxidase activity induced by hypoxia-reoxygenation injury and the production of reactive oxygen species. Allopurinol also decreases the concentration of intracellular Ca2+ increased by enhanced xanthine oxidase activity.In vivoAllopurinol shows abnormal pyrimidine metabolism together with renal toxicity which could be ameliorated by uridine, indicating that Allopurinol essentially causes pyrimidine metabolism abnormality leading to renal impairment in normal mice. Allopurinol increases urinary OD excretion to an extent similar to that in normal mice administered the same dose of Allopurinol in DNFB-sensitized mice. Allopurinol promotes a clinical improvement which is accompanied by a reduction in the parasitic load in the blood, skin and lymph nodes but, even after long period of allopurinol administration alone, Leishmania may persist in dog tissues in Leishmania-infected dogs. Allopurinol prevents early alcohol-induced liver injury in rats, most likely by preventing oxidant-dependent activation of NF-kappaB. Allopurinol protects dose-dependently against acetaminophen-induced cell injury, the loss of ATP and the increase of the GSSG content in the total liver and in the mitochondrial compartment without inhibiting reactive metabolite formation in mice. Allopurinol almost completely inhibits hepatic xanthine oxidase and dehydrogenase activity, but only high doses prevents the increase of the mitochondrial GSSG content.Cell Datacell lines：Concentrations：Incubation Time：Powder Purity:≥99%. Specification: 10mM in DMSO Molecular Formula: C5H4N4O Molecular Weight: 136.11